Amgen (AMGN) Stock Price, News & Analysis

Company Overview

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Key Stats

• Today's Range: $292.59 to $298.52
• 50-Day Range: $271.66 to $309.22
• 52-Week Range: $253.30 to $339.17
• Volume: 1.24 million shs
• Average Volume: 2.90 million shs
• Market Capitalization: $159.93 billion
• P/E Ratio: 27.15
• Dividend Yield: 3.20%
• Price Target: $307.27
• Consensus Rating: Hold

Amgen Stock Analysis - MarketRank™

Amgen scored higher than 91% of companies evaluated by MarketBeat, and ranked 97th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Amgen has received a consensus rating of Hold. The company's average rating score is 2.35, and is based on 8 buy ratings, 12 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Amgen has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 3.73%

Earnings Growth

Earnings for Amgen are expected to grow by 3.73% in the coming year, from $20.62 to $21.39 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amgen is 27.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.14.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amgen is 27.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.47.

Price to Earnings Growth Ratio

Amgen has a PEG Ratio of 2.61. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Amgen has a P/B Ratio of 27.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.74% of the float of Amgen has been sold short.

Short Interest Ratio / Days to Cover

Amgen has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Amgen has recently decreased by 0.34%, indicating that investor sentiment is improving.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Amgen pays a meaningful dividend of 3.16%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Amgen has been increasing its dividend for 14 years.

Dividend Coverage

The dividend payout ratio of Amgen is 86.86%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Amgen will have a dividend payout ratio of 44.51% next year. This indicates that Amgen will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -2.42

Percentage of Shares Shorted

2.74% of the float of Amgen has been sold short.

Short Interest Ratio / Days to Cover

Amgen has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Amgen has recently decreased by 0.34%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.35

News Sentiment

Amgen has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 45 news articles for Amgen this week, compared to 43 articles on an average week.

Search Interest

Only 41 people have searched for AMGN on MarketBeat in the last 30 days. This is a decrease of -2% compared to the previous 30 days.

MarketBeat Follows

Only 16 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Amgen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $434,520.00 in company stock.

Percentage Held by Insiders

Only 0.76% of the stock of Amgen is held by insiders.

Percentage Held by Institutions

76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AMGN Stock Analysis - Frequently Asked Questions

How have AMGN shares performed this year?

Amgen's stock was trading at $260.64 at the start of the year. Since then, AMGN stock has increased by 14.0% and is now trading at $297.03.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings data on Thursday, May, 1st. The medical research company reported $4.90 EPS for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. Amgen's quarterly revenue was up 9.4% on a year-over-year basis.
Read the conference call transcript.

Does Amgen have any subsidiaries?

Amgen subsidiaries include TeneoBio, Five Prime Therapeutics, Rodeo Therapeutics, Otezla, Nuevolution, Catherex, Catherex, and others.

Who are Amgen's major shareholders?

Top institutional shareholders of Amgen include Nordea Investment Management AB (0.53%), Sumitomo Mitsui Trust Group Inc. (0.32%), Envestnet Asset Management Inc. (0.28%) and Swedbank AB (0.14%). Insiders that own company stock include Amgen Inc, Murdo Gordon, David M Reese, Jonathan P Graham, Robert Eckert, Rachna Khosla, Nancy A Grygiel, Nancy A Grygiel and R Sanders Williams.
View institutional ownership trends.

How do I buy shares of Amgen?

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amgen investors own include NVIDIA (NVDA), Meta Platforms (META), Chevron (CVX), Verizon Communications (VZ), Bristol Myers Squibb (BMY), JPMorgan Chase & Co. (JPM) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/01/2025
• Record date for 6/6 Dividend: 5/16/2025
• Ex-Dividend for 6/6 Dividend: 5/16/2025
• Dividend Payable: 6/06/2025
• Today: 8/01/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AMGN
• CIK: 318154
• Web: www.amgen.com
• Phone: (805) 447-1000
• Fax: 805-447-1010
• Employees: 28,000
• Year Founded: 1980

Price Target and Rating

• Average Price Target for Amgen: $307.27
• High Price Target: $383.00
• Low Price Target: $195.00
• Potential Upside/Downside: +4.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.35
• Research Coverage: 23 Analysts

Profitability

• EPS (Trailing Twelve Months): $10.96
• Trailing P/E Ratio: 26.93
• Forward P/E Ratio: 14.31
• P/E Growth: 2.61
• Net Income: $4.09 billion
• Net Margins: 17.39%
• Pretax Margin: 19.49%
• Return on Equity: 176.11%
• Return on Assets: 12.39%

Debt

• Debt-to-Equity Ratio: 8.70
• Current Ratio: 1.17
• Quick Ratio: 0.88

Sales & Book Value

• Annual Sales: $33.42 billion
• Price / Sales: 4.75
• Cash Flow: $29.75 per share
• Price / Cash Flow: 9.92
• Book Value: $10.93 per share
• Price / Book: 27.00

Miscellaneous

• Outstanding Shares: 537,710,000
• Free Float: 533,619,000
• Market Cap: $158.68 billion
• Optionable: Optionable
• Beta: 0.49